NAD+ research monograph — the coenzyme, its precursors, and what the research shows

NAD+ is included in this library because it is widely sold and discussed
alongside peptides — but it is important to start with what it is not.

Chemical identity & structure.
NAD+ — nicotinamide adenine dinucleotide — is not a peptide. It is a
dinucleotide: two nucleotides (one carrying an adenine base, one carrying a
nicotinamide base) joined through a pair of phosphate groups. It is a coenzyme
present in every living cell. We cover it here because the research-compound
market treats it as adjacent to the peptide category, not because it belongs to
that chemical class.

Mechanism of action.
NAD+ is central to cellular metabolism in two roles. First, as a redox carrier:
the NAD+/NADH couple shuttles electrons in the reactions that extract energy
from nutrients. Second, as a consumed substrate for several enzyme families —
the sirtuins (involved in metabolic and stress-response signaling), PARPs
(involved in DNA repair), and CD38. Cellular NAD+ levels are reported to decline
with age, and the research interest centers on whether restoring those levels
produces measurable benefit.

Key research findings.
Most of the actionable research is on NAD+ precursors rather than NAD+
itself — principally nicotinamide riboside (NR) and nicotinamide mononucleotide
(NMN). Human studies have shown that oral precursors can raise blood NAD+
metabolite levels. Whether that translates into meaningful clinical or
functional benefit is far less settled — human outcome data is early-stage and
mixed.

The research / citation base.
Preclinical (rodent) research on NAD+ biology and precursors is extensive.
Human trials exist for NR and NMN and are growing, but they are mostly small,
short, and focused on biomarkers rather than hard outcomes. Direct NAD+
administration (for example by IV) has a much thinner evidence base than the
oral-precursor literature. Be skeptical of strong anti-aging claims — they run
ahead of the human data.

Research protocols in the literature.
Research has used oral precursors (NR, NMN), intravenous NAD+ infusions, and
subcutaneous NAD+ preparations. Protocols vary widely and there is no consensus
research protocol. IV NAD+ in particular is associated with infusion-related
discomfort in reports.

Quality & sourcing notes.
For a small molecule like NAD+ or its precursors, purity and identity should
still be documented on a batch-specific COA (HPLC purity; identity confirmation).
The supplement market for NMN/NR has had documented label-accuracy problems —
independent verification matters.

*Research-use note: Educational summary of published research. NAD+ and its
precursors are described here for research context only; nothing here is medical
advice.*